Monte Rosa Therapeutics Shares Rise Ahead of Study Results

Dow Jones

Jan 07

By Connor Hart

Shares of Monte Rosa Therapeutics climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases.

The stock rose 8.7% to $17.40 in after-hours trading Tuesday. Shares ended the regular session 11% higher at $16.01.

The biotechnology company said after the bell that management will host a conference call and webcast on Wednesday at 8:00 a.m. ET. The presentation will highlight interim clinical results from an ongoing Phase 1 study of its therapy, MRT-8102, a molecular glue degrader that targets NEK7, a protein thought to help regulate inflammation, for the treatment of inflammatory diseases.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 06, 2026 18:10 ET (23:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601846068"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601846068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601846068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 07:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601846068","market":"sh","top_or_hot":-1,"title":"Monte Rosa Therapeutics Shares Rise Ahead of Study Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases. \n</p>\n<p>\n  The stock rose 8.7% to $17.40 in after-hours trading Tuesday. Shares ended the regular session 11% higher at $16.01. \n</p>\n<p>\n  The biotechnology company said after the bell that management will host a conference call and webcast on Wednesday at 8:00 a.m. ET. The presentation will highlight interim clinical results from an ongoing Phase 1 study of its therapy, MRT-8102, a molecular glue degrader that targets NEK7, a protein thought to help regulate inflammation, for the treatment of inflammatory diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Shares Rise Ahead of Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Shares Rise Ahead of Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-07 07:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases. \n</p>\n<p>\n  The stock rose 8.7% to $17.40 in after-hours trading Tuesday. Shares ended the regular session 11% higher at $16.01. \n</p>\n<p>\n  The biotechnology company said after the bell that management will host a conference call and webcast on Wednesday at 8:00 a.m. ET. The presentation will highlight interim clinical results from an ongoing Phase 1 study of its therapy, MRT-8102, a molecular glue degrader that targets NEK7, a protein thought to help regulate inflammation, for the treatment of inflammatory diseases. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 18:10 ET (23:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601846068","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601846068","pubTimestamp":1767741000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Monte Rosa Therapeutics climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases.The stock rose 8.7% to $17.40 in after-hours trading Tuesday. Shares ended the regular session 11% higher at $16.01.The biotechnology company said after the bell that management will host a conference call and webcast on Wednesday at 8:00 a.m. ET. The presentation will highlight interim clinical results from an ongoing Phase 1 study of its therapy, MRT-8102, a molecular glue degrader that targets NEK7, a protein thought to help regulate inflammation, for the treatment of inflammatory diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","GLUE":"Monte Rosa Therapeutics"},"translate_title":"Monte Rosa Therapeutics股价在研究结果公布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Monte Rosa Therapeutics climbed after the company said it will host a call Wednesday to review results from an early-stage trial of its treatment of inflammatory diseases. \n\n\n  The stock rose 8.7% to $17.40 in after-hours trading Tuesday. Shares ended the regular session 11% higher at $16.01. \n\n\n  The biotechnology company said after the bell that management will host a conference call and webcast on Wednesday at 8:00 a.m. ET. The presentation will highlight interim clinical results from an ongoing Phase 1 study of its therapy, MRT-8102, a molecular glue degrader that targets NEK7, a protein thought to help regulate inflammation, for the treatment of inflammatory diseases. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 18:10 ET (23:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}